Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes

Ilias Attaye; Julia J. Witjes; Annefleur M. Koopen; Eduard W.J. van der Vossen; Diona Zwirs; Koen Wortelboer; Didier Collard; Elles Marleen Kemper; Maaike Winkelmeijer; Jens J. Holst; Stanley L. Hazen; Folkert Kuipers; Erik S.G. Stroes; Albert K. Groen; Willem M. de Vos; Max Nieuwdorp; Hilde Herrema

doi:10.1016/j.isci.2024.110455

Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes

Ilias Attaye, Julia J. Witjes, Annefleur M. Koopen, Eduard W.J. van der Vossen, Diona Zwirs, Koen Wortelboer, Didier Collard, Elles Marleen Kemper, Maaike Winkelmeijer, Jens J. Holst, Stanley L. Hazen, Folkert Kuipers, Erik S.G. Stroes, Albert K. Groen, Willem M. de Vos, Max Nieuwdorp, Hilde Herrema^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

This randomized, double-blind, placebo-controlled trial investigated the impact of 14-day Anaerobutyricum soehngenii L2-7 supplementation on postprandial glucose levels in 25 White Dutch males with type 2 diabetes (T2D) on stable metformin therapy. The primary endpoint was the effect of A. soehngenii versus placebo on glucose excursions and variability as determined by continuous glucose monitoring. Secondary endpoints were changes in ambulatory 24-h blood pressure, incretins, circulating metabolites and excursions of plasma short-chain fatty acids (SCFAs) and bile acids upon a standardized meal. Results showed that A. soehngenii supplementation for 14 days significantly improved glycemic variability and mean arterial blood pressure, without notable changes in SCFAs, bile acids, incretin levels, or anthropometric parameters as compared to placebo-treated controls. Although well-tolerated and effective in improving glycemic control in the intervention group, further research in larger and more diverse populations is needed to generalize these findings.

Original language	English
Article number	110455
Journal	iScience
Volume	27
Issue number	8
DOIs	https://doi.org/10.1016/j.isci.2024.110455
Publication status	Published - 16 Aug 2024

Keywords

Health sciences
Human metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.isci.2024.110455Licence: CC BY

https://edepot.wur.nl/671418Licence: CC BY

Cite this

Attaye, I., Witjes, J. J., Koopen, A. M., van der Vossen, E. W. J., Zwirs, D., Wortelboer, K., Collard, D., Kemper, E. M., Winkelmeijer, M., Holst, J. J., Hazen, S. L., Kuipers, F., Stroes, E. S. G., Groen, A. K., de Vos, W. M., Nieuwdorp, M., & Herrema, H. (2024). Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes. iScience, 27(8), Article 110455. https://doi.org/10.1016/j.isci.2024.110455

@article{800dccd1119d4edea9e529e3393c4b11,

title = "Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes",

abstract = "This randomized, double-blind, placebo-controlled trial investigated the impact of 14-day Anaerobutyricum soehngenii L2-7 supplementation on postprandial glucose levels in 25 White Dutch males with type 2 diabetes (T2D) on stable metformin therapy. The primary endpoint was the effect of A. soehngenii versus placebo on glucose excursions and variability as determined by continuous glucose monitoring. Secondary endpoints were changes in ambulatory 24-h blood pressure, incretins, circulating metabolites and excursions of plasma short-chain fatty acids (SCFAs) and bile acids upon a standardized meal. Results showed that A. soehngenii supplementation for 14 days significantly improved glycemic variability and mean arterial blood pressure, without notable changes in SCFAs, bile acids, incretin levels, or anthropometric parameters as compared to placebo-treated controls. Although well-tolerated and effective in improving glycemic control in the intervention group, further research in larger and more diverse populations is needed to generalize these findings.",

keywords = "Health sciences, Human metabolism",

author = "Ilias Attaye and Witjes, {Julia J.} and Koopen, {Annefleur M.} and {van der Vossen}, {Eduard W.J.} and Diona Zwirs and Koen Wortelboer and Didier Collard and Kemper, {Elles Marleen} and Maaike Winkelmeijer and Holst, {Jens J.} and Hazen, {Stanley L.} and Folkert Kuipers and Stroes, {Erik S.G.} and Groen, {Albert K.} and {de Vos}, {Willem M.} and Max Nieuwdorp and Hilde Herrema",

year = "2024",

month = aug,

day = "16",

doi = "10.1016/j.isci.2024.110455",

language = "English",

volume = "27",

journal = "iScience",

issn = "2589-0042",

number = "8",

}

Attaye, I, Witjes, JJ, Koopen, AM, van der Vossen, EWJ, Zwirs, D, Wortelboer, K, Collard, D, Kemper, EM, Winkelmeijer, M, Holst, JJ, Hazen, SL, Kuipers, F, Stroes, ESG, Groen, AK, de Vos, WM, Nieuwdorp, M & Herrema, H 2024, 'Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes', iScience, vol. 27, no. 8, 110455. https://doi.org/10.1016/j.isci.2024.110455

TY - JOUR

T1 - Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes

AU - Attaye, Ilias

AU - Witjes, Julia J.

AU - Koopen, Annefleur M.

AU - van der Vossen, Eduard W.J.

AU - Zwirs, Diona

AU - Wortelboer, Koen

AU - Collard, Didier

AU - Kemper, Elles Marleen

AU - Winkelmeijer, Maaike

AU - Holst, Jens J.

AU - Hazen, Stanley L.

AU - Kuipers, Folkert

AU - Stroes, Erik S.G.

AU - Groen, Albert K.

AU - de Vos, Willem M.

AU - Nieuwdorp, Max

AU - Herrema, Hilde

PY - 2024/8/16

Y1 - 2024/8/16

N2 - This randomized, double-blind, placebo-controlled trial investigated the impact of 14-day Anaerobutyricum soehngenii L2-7 supplementation on postprandial glucose levels in 25 White Dutch males with type 2 diabetes (T2D) on stable metformin therapy. The primary endpoint was the effect of A. soehngenii versus placebo on glucose excursions and variability as determined by continuous glucose monitoring. Secondary endpoints were changes in ambulatory 24-h blood pressure, incretins, circulating metabolites and excursions of plasma short-chain fatty acids (SCFAs) and bile acids upon a standardized meal. Results showed that A. soehngenii supplementation for 14 days significantly improved glycemic variability and mean arterial blood pressure, without notable changes in SCFAs, bile acids, incretin levels, or anthropometric parameters as compared to placebo-treated controls. Although well-tolerated and effective in improving glycemic control in the intervention group, further research in larger and more diverse populations is needed to generalize these findings.

AB - This randomized, double-blind, placebo-controlled trial investigated the impact of 14-day Anaerobutyricum soehngenii L2-7 supplementation on postprandial glucose levels in 25 White Dutch males with type 2 diabetes (T2D) on stable metformin therapy. The primary endpoint was the effect of A. soehngenii versus placebo on glucose excursions and variability as determined by continuous glucose monitoring. Secondary endpoints were changes in ambulatory 24-h blood pressure, incretins, circulating metabolites and excursions of plasma short-chain fatty acids (SCFAs) and bile acids upon a standardized meal. Results showed that A. soehngenii supplementation for 14 days significantly improved glycemic variability and mean arterial blood pressure, without notable changes in SCFAs, bile acids, incretin levels, or anthropometric parameters as compared to placebo-treated controls. Although well-tolerated and effective in improving glycemic control in the intervention group, further research in larger and more diverse populations is needed to generalize these findings.

KW - Health sciences

KW - Human metabolism

U2 - 10.1016/j.isci.2024.110455

DO - 10.1016/j.isci.2024.110455

M3 - Article

AN - SCOPUS:85199139007

SN - 2589-0042

VL - 27

JO - iScience

JF - iScience

IS - 8

M1 - 110455

ER -

Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this